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Abstract
Over the past decade, many studies have found disproportionally higher prostate
cancer among men of African ancestry, and testicular cancer incidences among men of
European ancestry, compared with men from other ethnicity/race groups. However, genetic
determinants that could potentially explain this observation are unclear. This study
collected single nucleotide polymorphisms (SNPs) related to the two cancer types and
compared the frequencies of each risk allele of SNPs among men of African or European
ancestry from several genetic databases. When comparing the frequencies of risk alleles
that are associated with prostate and testicular cancers, significant differences were found
between those of African descendants and European descendants. As the second part of
this thesis, we investigated the roles of genetic in the reversal relationship observed
between asthma and all cancer risks. Single Nucleotide Polymorphisms that were reported
to be associated with asthma were collected and identified first and the cancer risks related
to each variant were reviewed in the hope to provide genetic basis for future pathway
analysis.
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Chapter 1: Racial Disparities in the Risk of Prostate and
Testicular Cancers
Introduction
Prostate cancer (PCa) and testicular cancer, also known as testicular germ cell
tumor (TGCT), are common cancers diagnosed in men globally. As the fourth most
common cancer globally, prostate cancer has incidence rates that vary more than 25-fold
worldwide. Within the United States, racial differences exist in prostate cancer incidence
rates, with African American Men exhibiting the highest reported incidence rates. While
Whites in the U.S. showed an incidence of 130.4 per 100,000 men, African American men
showed a high yearly incidence of 214.5 per 100,000 men between 2008 and 2012. 1
Although access to care and socioeconomic status may play a role in explaining this racial
disparities, overall data suggests that increased androgen stimulation of the prostate among
the black men could explain in part the higher incidence rates of prostate cancer in black
than in white.2 Testicular cancer is a much less common disease when compared with
prostate cancer. In 2012, the estimation was 5.6 per 100,000 men for new diagnose.
However, it is still one of the most common cancer diagnosed in men aged 15 to 35 years. 1
Similar to PCa, racial differences were also found in TGCT incidence rates, only with an
opposite trend. Globally, Western and Northern European nations have the highest
incidence rates (8.0 – 9.0 per 100,000) and African nations only have less than 1 per
100,000.1 Within the U.S., non-Hispanic Whites had the highest incidence rates followed
by blacks, Hispanic Whites and Asians and Pacific Islanders.3 The biological mechanisms
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behind this racial difference, however, is yet to be investigated, so is the opposite trend
seen in the racial disparities in the risks of both cancers. Thus, to understand how genetic
factors could play a role in the etiology of both cancers, this study analyzed genetic variants
related to either prostate cancer or testicular cancer to examine whether the risk allele
frequency could help investigate the observed incidence disparities in men of African
ancestry and European ancestry.

Literature Review
The biological mechanisms behind this racial disparity in the prostate cancer risk
among African descendants and European descendants have been investigated by some
research studies. On the cellular level, for example, Nicolas et al. compared the molecular
and genetic profiles of the normal epithelium and adenocarcinoma cells between a new
African American prostate cell model and paired normal and cancer epithelial cells from
the same patient. It was demonstrated that normal Conditionally Reprogrammed (CR) cells
expressed high levels of basal cell markers, including KRT5 and TP63, but low androgen
receptor (AR). Tumor CR cells from the African American patients on the other hand
expressed a significantly high level of luminal marker and EMT markers (PD-L1, TIMP3
and PAI1).4 Another study, similarly, confirmed that there is a significant difference of AR
protein expression between African men and white men. It was found that AR protein
expression was 22% higher in the benign prostate and 81% higher in the PCa in black
African men than in white men.2 On the genetic level, many studies have attempted to find
the associations and mechanisms behind the observation. For example, a case-control
analysis was conducted to determine if two polymorphisms within IGF-1 and one singlenucleotide polymorphism (SNP) in the IGFBP-3 gene were associated with serum IGF
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level variations and risk for PCa in African American men. They revealed that variation in
the 5’-untranslated region of the IGF-1 and IGFBP-3 genes may influence IGF serum levels
and PCa risks in African American men.5
With a 70% increasing incidence among Caucasian males in the last 20 years,
TGCT is expected to have carcinoma in situ, originating from an embryonic germ cell
blocked in its maturation process. Since 2009, several genome wide association studies
(GWAS) have reported on SNPs that have significant associations with TGCT
development, in or near the genes KITLG, SPRY4, BAK1, DMRT1, TERT, ATF7IP,
HPGDS, MAD1L1, RFWD3, TEX14, and PPM1E.6 However, compared with prostate
cancer, although multiple studies have observed and reported the racial disparity that men
of European ancestry tend to have higher incidence rates of testicular cancer than men of
African ancestry, few have dug deeper on the genetic mechanism that could potentially
explain this relationship, not to mention the opposite trend that men of African ancestry
and European ancestry have disproportionately higher incidences in prostate cancer and
testicular cancer, respectively. Thus, by comparing the risk allele frequencies of the SNPs
reported to have associations with these two cancers, this study takes the first step to
understand this opposite trend of racial disparities on another genetic level, in the hope to
provide building blocks for further genetic pathway analysis.

Research Design
Literature search was performed by using combinations of key words including,
single nucleotide polymorphism (SNP), Genome Wide Associate Study (GWAS), genetic
risk variant, prostate cancer, and testicular cancer. Genome-wide association studies and
meta-analysis of genome wide association were analyzed to identify all the SNPs
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associated studies with Testicular Cancer and Prostate Cancer. SNPs that present risk
effects to the two cancer types at a statistically significant level were collected. A total of
230 risk SNPs significantly associated with prostate cancer and 80 risk SNPs associated
with testicular cancer were identified (Supplementary Table 1, 2). One SNP (rs4624820)
with conflicting results from two different studies was excluded from the further analysis.
Data of risk and reference alleles, odds ratio (OR), confidence interval (CI), p-value, gene
symbol, ethnic group, number of cases and controls, and citation of original publications
were collected and included in supplementary tables. When there were multiple ORs
present in the study, we only presented the ones from meta-analysis studies. Risk allele
frequencies of these identified SNPs in populations of African and European ancestry were
then obtained from 3 databases: 1000 Genomes Project, Allele Frequency Aggregator
(ALFA), and the genome Aggregation Database (gnomAD). 1000 Genomes Project
database contains data for 2,504 individuals from 26 populations.7 ALFA database has over
2 million subjects from 12 diverse populations.8 GnomAD has a total of 141,456
individuals in the 15,708 genomes sequenced.9 Number of individuals with available allele
frequency data for each SNP in these 3 databases were included in Supplementary Table 1
and 2 as well.

The hypothesis that higher/lower incidence of prostate/testicular cancer could be
associated with higher/lower average frequency of risk alleles was tested by comparing
risk allele frequencies between European and African populations. Allele frequencies in
different databases vary slightly and frequency of each risk allele (F) was calculated by
averaging frequencies in these 3 databases with justification for sample sizes. To further
account for attributable risk of risk alleles, weighted frequency (Fw) that was calculated
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with the equation: Fw=F*OR/ORmax, where OR is the corresponding odds ratio of the risk
allele and ORmax is the largest odds ratio among risk alleles. Average weighted
frequencies of risk alleles were then compared between the 2 racial/ethnic group using onetailed student’s t-test because the testing hypotheses have one direction of interest for each
cancer type.

Results and Discussions
The results showed that for prostate cancer, the average risk allele frequency (F)
was significantly higher in men of African ancestry (45%) compared to men of European
ancestry (42%) (p=0.043). After considering the odds ratio of risk alleles, the analysis of
weighted frequencies (Fw) stayed highly significant (p=0.023) (Figure 1.1a). On the
contrary, the average risk allele frequency of testicular cancer was significantly lower in
men of African ancestry (46%) compared to men of European ancestry (51%) (p=0.029).
The weighted analysis showed the same significant difference (p=0.014) (Figure 1.1b).
Moreover, frequencies of all risk alleles in African (Y axis of Figure 2) and
European (X axis of Figure 2) populations showed significant linear regression
relationships in both prostate cancer (Y=1.16*X-0.012, p<0.0001) and testicular cancer
(Y=0.71*X+0.037, p<0.0001). Deming regression analysis was performed to find the line
of best fit by accounting for frequency variations on both the x- and the y- axis. Regression
lines from both cancer types were compared to a standard regression line that has equal
allele frequencies in both African and European populations (slope=1). The differences
between the slopes were highly significant where the regression line of prostate cancer data
(slope=1.246, p=0.0051, Figure 1.2a) skewed above the standard line towards the African
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population and the regression line of testicular cancer data (slope=0.711, p<0.0001, Figure
1.2b) skewed below the standard line slope towards the European population.
Consistent with the results from international comparisons, the significant
differences of risk allele frequencies in related SNPs demonstrated in the study suggests
that the variations and racial disparities between African and European descendants could
be underpinned by genetically determined variations in susceptibility or other
constitutional factors. Moreover, epigenetic factors such as dietary or other modifiable
factors could exert an important influence and potentially modify this observed association.
For example, a study in UK found that unlike Asians in Asia and Bangladeshi and Chinese
migrants to England, the Indian and Pakistani men in England were shown to have similar
or even higher incidence rate of prostate cancer than White men. 10 Thus, the convergence
of incidence rates of prostate cancer among Indian and Pakistani people towards the local
rate after a large number of migration suggests that there might be epigenetic factors behind
the observation.

Conclusion
Results from both t-test and regression analysis are consistent with each other,
which indicate that men of African ancestry are more likely to have risk alleles of prostate
cancer and less likely to have risk alleles of testicular cancer compared to men of European
ancestry. These findings suggest that genetic factors could partially explain the greater
burden of prostate cancer on men of African ancestry and the higher incidence of testicular
in men of European ancestry compared to other racial/ethnic groups. Cancer is a complex
disease that normally involves multiple genes and environmental factors in its etiology.
Therefore, in addition to understanding the influence of genetic factors, social and
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environmental factors also need to be considered when analyzing the observed racial and
ethnic disparities in the risk of prostate and testicular cancers.

Figure 1. 1
Figure1. 1: Comparison of risk allele frequencies of prostate and testicular cancers
between men of African descent and European descent. a) Average weighted risk
allele frequency of prostate cancer was significantly higher in men of African
descent compared to men of European ancestry descent (p=0.023). b) Average
weighted risk allele frequency of testicular cancer was significantly lower in men of
African descent compared to men of European descent (p=0.014).

Figure 1. 2
Figure 1.2: Regression lines of risk allele frequencies between African and European
descent for prostate and testicular cancers. a) The regression line of prostate cancer
data (slope=1.16) skewed above the standard line (slope=1) towards African population.
The differences between the slopes were highly significant (p<0.0001). b) The regression
line of testicular cancer data (slope=0.71) skewed below the standard line slope (slope=1)
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towards European population. The differences between the slopes were highly significant
(p<0.0001).

Chapter 2: Asthma and Cancer Risks
Introduction
In the past decades, epidemiologic studies have shown that people with asthma
present a significantly lower risk of several types of cancers, such as myeloma, melanoma,
pancreatic cancer, non-Hodgkin’s lymphoma, stomach cancer, colorectal cancer, glioma
and leukemia. However, the mechanisms responsible for the protective role of this atopic
disease against certain malignancies are not fully understood. This study took advantage
of available genome-wide association and expression data to identify genetic variants and
possible biological pathways associated with both diseases that may play diametric roles
in cancer and asthma development, in the hope to help explain the observed inverse
relationship between them.
As a complicated condition with chronic airway inflammation and airway hyperreactivity, asthma usually shows symptoms such as recurrent wheezing, coughing and
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shortness of breath.11 The presence of immunoglobulin E (IgE)-mediated immune
reactions is the main characterization of atopic disease such as asthma, and it is
hypothesized that these IgE-mediated immune reactions may play a role in
immunosurveillance against cancer.12 Therefore, it is possible that people with asthma, a
condition commonly characterized by IgE-mediated atopic reactions, may develop an IgEmediated response against neoplasms that could reduce cancer risks. While several studies
have observed the inverse relationship between history of asthma and risk of various
cancers, there is a lack of confirmation and consistency of this relationship. For example,
some studies have shown that the inverse associations between atopic conditions including
asthma and glioma were limited to white persons, with no association observed among the
black population.13 However, genetic studies that could potentially explain the biological
mechanisms and genetic pathways for this reversal relationship and the racial differences
are very limited.
This study provides genetic bases for the reversal relationship between asthma and
cancer risks by identifying genetic variants associated with asthma, searching and
reviewing cancer risks related to the identified genetic variants, and detecting pathways of
the genes that present the diametric role. This study also presents a thorough search of the
cancer risks in the asthma-related genes for further haplotype investigations.
By leveraging recently available genome-wide genotyping and expression data, this
study tackles a field that presented difficulties to study previously because comprehensive
databases needed to identify clinical correlations between chronic disease and cancer risk
were not commonly annotated for these anti-correlations. Understandings of the
biochemical and genetic bases for the inverse asthma-cancer relationship may reveal novel
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insights into the mechanisms underlying the etiology and development of these two
diseases, which may, in turn, provide information to the development of therapeutic and
preventive techniques for new molecular targets and form a powerful basis for future
research.

Literature Review
As one of the first researchers who discovered the inverse relationship between
asthma and cancer risks, in early 1960, Fisherman reported that atopic disease was
significantly less common in patients with malignant disease than in age-matched
controls.14 A few years later in 1974, a study of 765 men and 1127 women with asthma
reported that deaths from all cancers excluding lung cancer were significantly reduced in
both men and women.15 In 1993, a record-linkage study in Swedish hospitals for asthma
revealed a marked reduction of cancer incidence among the 64,346 people treated
compared with the general population. Risks of multiple myeloma, malignant melanoma,
breast cancer, uterine body cancer and stomach cancer were observed to reduce. 16
Moreover, a prospective cohort study in the U.S. with 1,102,247 subjects revealed a
significant inverse association between overall cancer and colorectal cancer mortality and
a history of both asthma and hay fever after 18 years of follow-up.17
More specifically, atopic allergic conditions (AACs) including asthma appeared in
many epidemiology studies to have protective roles in cancers such as colorectal cancer,
pancreatic cancer, leukemia, glioma and Non-Hodgkin Lymphoma. According to a
multiethnic cohort study with 4,834 incident colorectal cancer (CRC) cases and 1,363
CRC-related death in the U.S., AACs were associated with a reduced risk of CRC incidence
among both men and women (RR=0.86).18 For pancreatic cancer, according to a
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epidemiology review study, eight of the ten studies examining the associations between
atopy and pancreatic cancer show a reversal relationship.19 A case-control study with 1297
ductal adenocarcinoma of the pancreas (PDAC) cases and 1024 controls found that asthma
was associated with lower risk of PDAC (OR=0.64).20 Likewise, multiple studies found an
inverse association between allergy, asthma or atopy with acute lymphoblastic leukemia
(ALL), regardless of specific exposure.19 For example, a national registry-based casecontrol study carried out by France in 2003-2004 observed a negative association between
ALL and history of asthma (OR=0.7).21 For primary brain tumors such as glioma, many
studies suggested an inverse relationship as well. A 2007 analysis that investigated the
relationship between allergic conditions and glioma prevalence in 1527 cases from
Denmark, Finland, Norway, Sweden and the UK found a significant 30% lower odds of
glioma among adults with asthma history.22 Similarly, a US-based case-control study
assessed the associations between self-reported asthma and glioma among 489 glioma
patients, and found a significant result that asthma was associated with decreased odds of
glioma (OR=0.6).23 As for non-Hodgkin lymphoma (NHL), recent pooled analyses support
the inverse relationship as well. A pooled analysis of data on atopic disease and risk NHL
from 13 case-control studies, including 13,535 cases and 16,388 controls, found that a
history of asthma was associated with a 10% reduction in overall NHL and B-cell NHL in
individuals who reported at least one other atopic condition.24
Despite the strong evidence for the inverse association between asthma and risk for
certain cancer types, however, very few studies have investigated the molecular basis
underlying this association. To provide building blocks for future pathway-based analysis
to facilitate the identification of novel molecular networks, this his study explored GWAS
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and genome-wide expression data to identify and study genes involved in the development
of both diseases.

Research Design
Since it is hypothesized that some genes are involved but play diametric roles in
both asthma and cancer development, identifying genes that are associated with both
asthma and cancers is essential. More specifically, single nucleotide polymorphisms (SNPs)
associated with both diseases should be identified, since they allow scientists to evaluate
individuals’ genetic predispositions to develop diseases.25 Thus, as the first step, SNPs
associated with increased risk of asthma but reduced risk of cancer were identified.
Literature search was performed by using combinations of key words including, single
nucleotide polymorphism (SNP), Genome Wide Associate Study (GWAS), genetic risk
variant and asthma. GWAS and meta-analysis of genome wide association were analyzed
to identify all the SNPs associated studies associated with asthma. SNPs that present risk
effects to asthma at a statistically significant level were collected. With all the identified
SNPs associated with asthma, literature search was then performed to find if any of the
SNPs was associated with cancer risks by a combination of key words including the
specific SNP number and cancer. Asthma related SNPs that were found to be associated
with any cancer type were collected, regardless of the association direction.
Consequently, an exhaustive literature search was performed to find cancer risks
related to all the genes that present risks to asthma with key words including the specific
gene symbol, cancer and genetic variant, single nucleotide polymorphisms. Case-control
studies that reveal the cancer risks associated with the specific genes and present genotype
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information (SNPs) about the genes were included for future pathway analysis
(Supplementary Table 4).

Results
A total of 169 SNPs that are reported to increase the risks of asthma incidents were
identified and collected (Supplementary Table 3). Data of risk allele, reference allele,
odds ratio (OR), confidence interval (CI), p-value, gene symbol (if applicable) and citation
of original publications were included.
SNPs associated with both asthma and cancer risks were collected (Table 2.1). A
total of 22 SNPs were found to have associations with cancers such as glioma, colorectal
cancer and rectal cancer, lung cancer, breast cancer and cervical cancer. Among the 22
SNPs, 10 of them were reported to have statistical significances, and 7 (rs2284033,
rs1800797, rs12956924, rs1801275, rs1800896, rs20541, rs1800925) of them were
reported to show a reverse relationship between the two diseases because the risk alleles of
asthma played a protective role in cancer risks. Such reversal association is represented
when the odds ratio of the asthma risk allele is bigger than 1 while the odds ratio in cancer
of the same allele is smaller than 1, or when the odds ratio of the reference allele for asthma
is bigger than 1 for the cancer risk (rs1800896). For rs1800925, the reversal relationship is
shown by the odds ratio of the heterozygous genotype CT (T as the risk allele for asthma)
is smaller (OR=0.76) than that of the homozygous genotype CC (OR=1) for glioma risk.
4 SNPs that present significant associations between asthma and cancer risks are
reported to have a positive relationship: rs1800925, rs1535, rs2066844 and rs1805010. The
positive relationship is shown when the risk allele of asthma has an odds ratio that is greater
than 1 for the cancer risks. For rs1805010, this relationship is shown by a different set of
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alleles (C and T), instead of G and A seen in the asthma risk and reference alleles because
the opposite trend of gene was genotyped in the original paper (PMID: 25785117). Among
the 22 SNPs that present associations between the two diseases, 12 of them have results
that are not statistically significant.

Discussion
Glioma is one of the cancer types that have been found the most frequently to have
reversal relationships with asthma in this study. Four SNPs in this study are found to
present this diametric role with a statistical significance (rs1801275, rs1800896, rs20541,
rs1800925), and seven SNPs with insignificant results (rs62026376, rs10197862,
rs1837253, rs7009110, rs72699186, rs17294280, rs62026376). As one of the most
aggressive human tumors, glioma is responsible for 80% of primary malignant brain
tumors with high mortality rates. In fact, it has been long suspected that a history of asthma
and higher levels of immunoglobulin E (IgE) could play a protective role against glioma
development and prognosis.26
In this study, two SNPs (rs20541 and rs1800925) (Table 2.1) that present this
significantly reversal association are from a same gene: IL-13. Not surprisingly, it has been
suggested that IL-13 is positively associated with asthma development and higher IgE
levels, and individuals that are genetically capable of producing higher levels of IL-13
cytokine may be protected from glioma.27 Shin et al. found that by inducing death of
activated microglia, which is the major inflammatory cell of the central nervous system,
IL-13 controls brain inflammation and enhances neuronal survival.28 It is also indicated
that IL-13 is central to a novel immunoregulatory pathway in which NKT cells suppress
tumor immunosurveillance.29 Thus, although the functional relevance of IL-13 is not
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completely understood, the negative associations between IL-13 and glioma collected and
reviewed by this study adds more genetic proof to the protective role of IL-13 against
glioma.
SMAD7 is another gene involved in inflammation-related pathways that shows a
reversal association between cancer and asthma (rs12956924). SMAD7 modulates
transforming growth factor-, whose signaling pathway plays an important role in cancer
initiation and progression, and Wnt signaling, which is central to the development of
colorectal cancer (CRC).30 It is also indicated in another study that the SMAD7-mediated
plastic effect on T-cell phenotype induces protection against colorectal cancer.31 However,
SMAD7 polymorphisms can also be associated with increased risks of colon cancer. For
example, rs12953717 in the SMAD7 gene is observed to have significant associations with
increased risk of colon cancer.32 It is also reported that CRC patients with deletion of
SMAD7 have a significantly better prognosis than patients with two copies of this gene,
while increased copy numbers of SMAD7 are associated with a significantly worse
prognosis.33 Thus, the contribution of SMAD7 in CRC is still unclear, and a better
understanding of its role in future researches could help to determine if SMAD7 could
serve as a molecular target for future CRC pharmacological interventions.
Interestingly, IL4R is observed to have SNPs related to both positive and negative
associations with cancer risks and asthma: allele G of rs1801275 has a protective
association against glioma whereas allele G of rs1805010 has a positive association with
increased risk for renal cell cancer (Table 2.1). Though lacks further investigation, genetic
explanations for the two phenomena were attempted by several studies. Genetic factors are
likely to exist in linkage disequilibrium with particular haplotypes in IL4R and IL 13 that
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affects the risk of brain cancer such as glioma and likely via an immune mechanism.27 On
the other hand, type II IL4R, which consists of the IL13R1 and IL4R subunits, is
overexpressed in many epithelial tumors, including renal cell carcinoma. In fact, the
expression of IL4R is so robust on the cancer cells that it has been used for anti-cancer
toxins as a targeting molecule.34 Therefore, future studies of the functionalities of IL4R
and IL4/IL4R axis are warranted to understand their effects on cancer risks.

Conclusions
As the first step to investigate the molecular basis underlying the reversal
association between asthma and risks for certain cancer types by literature reviewing, this
study provided more genetic proof to the protective roles of genes such as IL13 against
cancers such as glioma. Additionally, this study also demonstrated the contracting roles of
a single gene (SMAD7 and IL4R) in the same or different types of cancers.
Although this study provides a fairly thorough list of SNPs associated with asthma,
it is believed that more could be identified. Possible reasons for failure to find significant
associations between some SNPs and asthma include both the relatively small numbers of
controls reporting asthma and misclassification of the condition due to screening or selfreport differences.35 For example, self-reported asthma history by questionnaire as a
measure of asthma status could misclassify exposure, since the difference between asthma
and conditions that exhibit similar symptoms may decrease the accuracy of exposure
measurement. Similarly, due to differences in exposure definition or covariate adjustment,
small sample sizes, multiple testing, and/or heterogeneity in study populations, it is
possible that differences across studies of SNPs and cancer risks may arise. Additionally,
epigenetic factors might also play important roles. For example, it is possible that some
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genes that are associated with asthma can also interact with environmental factors and
present different significant results in different studies. Similarly, heterogeneity in study
environment might also confound the results as pollutant effect might amplify the results
among those who are genetically susceptible. Thus, results that showed statistically
insignificant were still presented for future investigation because of the methodological
limitations existing in the individual epidemiological studies (Table 2.2).
Moreover, although this study provides a clear evidence for the reversal association
between asthma and certain cancer risks, the temporal relationship between exposure and
outcome is yet to be determined. Whether asthma is a protective/risk factor or the other
way around still needs further investigation of the molecular pathways.
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Table 2. 1
Table 2. 1: SNPs associated with both asthma and cancer that have statistical significance
SNP

Gene

Risk
Allele

Ref
Allele

OR

rs2284033

IL2RB

G

A

1.12

rs1800797

IL6/LOC54147
2

G

A

1.04

rs12956924

SMAD7

A

G

1.04

rs12956924

SMAD7

A

G

1.04

rs1801275

IL4R

G

A

2.12

rs1800896

IL19

A

G

1.84

rs20541

IL13

A

G

2.13

rs1800925

IL13

T

C

1.46

CI
1.081.16
1.031.06
1.021.05
1.021.05
1.393.22
1.2–3.87
1.393.26
0.982.19

rs1800925

IL13

T

C

1.46

0.982.19

rs1800925

IL13

T

C

1.46

0.982.19

rs1535

FADS2

A

G

1.05

1.041.06

21

Cancer related

Cancer OR

Cancer
p-value

Lung Cancer

0.56 (0.32–0.96)

0.031

Breast Cancer

0.77(0.57-1.04)

<0.05

Rectal Cancer

0.66(0.45-0.97)

0.03

Colorectal

0.77(0.59-1.00)

0.048

Glioma

0.81 (0.69-0.95)

0.011

Glioma

GG: 1.39 (0.94–2.09)

0.021

Glioma

TT: 0.39 (0.16–0.93)

0.023

Glioma

CT vs. CC: 0.76 (0.571.0)

0.05

2.08(1.32–3.28)

7.79 ×
10−4

TT:2.27 (1.19–4.31)

0.012

1.07 (1.04–1.11)

4.12 ×
10−5

Breast Cancer
(Same
Direction)
Colon Cancer
(Same
Direction)
Colorectal
Cancer (Same
Direction)

rs2066844

NOD2

T

C

1.09

1.061.12

rs2066844

NOD2

T

C

1.09

1.061.12

rs1805010

IL4R

G

A

1.60

1.012.53

Cancer Risk
(Same
Direction)
Colon Cancer
(Same
Direction)
Renal Cell
Cancer (Same
Direction)

1.43(1.09–1.88)

0.01

8.7(2.2-23.4)

0.002

CC/CT vs. TT:1.266
(1.09-1.472)

0.002

Table 2. 2
Table 2. 2: SNPs associated with both asthma and cancer that have no statistical significance (P-value > 0.05)
SNP

Gene

Risk
Allele

rs1805015

IL4R

T

C

1.45

1.17-1.80

rs7212938

GSDMA

G

T

1.16

1.11–1.22

rs10197862
rs760517

IL1RL1
NCF4

A
T

G
C

1.19
1.04

1.17-1.21
1.03-1.05

rs4833095

TLR1

T

C

1.20

1.14–1.26

rs3813308
rs1837253
rs7009110
rs72699186

TNFAIP8

G
C
T
T

C
T
C
A

1.04
1.11
1.14
1.26

1.03-1.05
1.1-1.13
1.09–1.19
1.17–1.36

T

G

1.17

1.13–1.21

G
C

A
T

1.18
1.17

1.12–1.25
1.11–1.23

rs2155219
rs17294280
rs62026376

SMAD3
CLEC16A/LOC105371081

Ref
Allele

OR

CI

Cancer OR
Glioblastoma

22

Glioma (Same
Direction)
Glioma
Breast Cancer
Glioma (Same
Direction)
Cervical Cancer
Glioma
Glioma
Glioma
Glioma (Same
Direction)
Glioma
Glioma

Cancer p-value
TC, CC vs. TT:
1.08 (0.70-1.66)
1.00 (0.97−1.04)
0.98 (0.93−1.03)
0.89(0.68-1.15)
1.03 (0.99−1.08)
0.82 (0.51–1.30)
0.96 (0.93−1.00)
0.98 (0.94−1.01)
0.97 (0.93−1.02)
1.01 (0.97−1.05)
0.98 (0.94−1.03)
0.97 (0.93−1.01)

References
1. Filippou, P., Ferguson, J. E. & Nielsen, M. E. Epidemiology of Prostate and Testicular
Cancer. Semin. Interv. Radiol. 33, 182–185 (2016).
2. Gaston, K. E., Kim, D., Singh, S., Ford, O. H. & Mohler, J. L. Racial Differences in Androgen
Receptor Protein Expression in Men With Clinically Localized Prostate Cancer. J. Urol. 170,
990–993 (2003).
3. Li, Y., Lu, Q., Wang, Y. & Ma, S. Racial differences in testicular cancer in the United States:
descriptive epidemiology. BMC Cancer 20, 284 (2020).
4. Nicolas, N. et al. African-American Prostate Normal and Cancer Cells for Health Disparities
Research. in Human Cell Transformation: Advances in Cell Models for the Study of Cancer
and Aging (eds. Rhim, J. S., Dritschilo, A. & Kremer, R.) 101–108 (Springer International
Publishing, 2019). doi:10.1007/978-3-030-22254-3_8.
5. Hernandez, W. et al. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate
cancer risk in African-Americans. Carcinogenesis 28, 2154–2159 (2007).
6. Elzinga-Tinke, J. E., Dohle, G. R. & Looijenga, L. H. Etiology and early pathogenesis of
malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis. Asian J.
Androl. 17, 381–393 (2015).
7. Sudmant, P. H. et al. An integrated map of structural variation in 2,504 human genomes.
Nature 526, 75–81 (2015).
8. ALFA: Allele Frequency Aggregator. https://www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/.
9. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in
141,456 humans. Nature 581, 434–443 (2020).

23

10.

Jack, R. H., Davies, E. A. & Møller, H. Testis and prostate cancer incidence in ethnic

groups in South East England. Int. J. Androl. 30, 215–221 (2007).
11.

Rava, M. et al. Asthma status is associated with decreased risk of aggressive urothelial

bladder cancer. Int. J. Cancer 142, 470–476 (2018).
12.

Kantor, E. D., Hsu, M., Du, M. & Signorello, L. B. Allergies and asthma in relation to

cancer risk. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored
Am. Soc. Prev. Oncol. 28, 1395–1403 (2019).
13.

Krishnamachari, B. et al. A Pooled Multisite Analysis of the Effects of Atopic Medical

Conditions in Glioma Risk in Different Ethnic Groups. Ann. Epidemiol. 25, 270–274 (2015).
14.

Fisherman, E. W. Does the allergic diathesis influence malignancy? J. Allergy 31, 74–78

(1960).
15.

Alderson, M. MORTALITY FROM MALIGNANT DISEASE IN PATIENTS WITH

ASTHMA. The Lancet 304, 1475–1477 (1974).
16.

Källén, B., Gunnarskog, J. & Conradson, T. B. Cancer risk in asthmatic subjects selected

from hospital discharge registry. Eur. Respir. J. 6, 694–697 (1993).
17.

Turner, M. C. et al. Cancer Mortality among US Men and Women with Asthma and Hay

Fever. Am. J. Epidemiol. 162, 212–221 (2005).
18.

Tambe, N. A. et al. Atopic allergic conditions and colorectal cancer risk in the

Multiethnic Cohort Study. Am. J. Epidemiol. 181, 889–897 (2015).
19.

Cui, Y. & Hill, A. W. Atopy and Specific Cancer Sites: a Review of Epidemiological

Studies. Clin. Rev. Allergy Immunol. 51, 338–352 (2016).
20.

Gomez-Rubio, P. et al. Reduced risk of pancreatic cancer associated with asthma and

nasal allergies. Gut 66, 314–322 (2017).

24

21.

Rudant, J. et al. Childhood acute leukemia, early common infections, and allergy: The

ESCALE Study. Am. J. Epidemiol. 172, 1015–1027 (2010).
22.

Wigertz, A. et al. Allergic conditions and brain tumor risk. Am. J. Epidemiol. 166, 941–

950 (2007).
23.

Brenner, A. V. et al. History of allergies and autoimmune diseases and risk of brain

tumors in adults. Int. J. Cancer 99, 252–259 (2002).
24.

Vajdic, C. M. et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph

pooled analysis. Cancer Res. 69, 6482–6489 (2009).
25.

single nucleotide polymorphism / SNP | Learn Science at Scitable.

https://www.nature.com/scitable/definition/snp-295/.
26.

Amirian, E. et al. Genetic variants in inflammation pathway genes and asthma in glioma

susceptibility. Neuro-Oncol. 12, 444–452 (2010).
27.

Wiemels, J. L. et al. Allergy-related polymorphisms influence glioma status and serum

IgE levels. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored
Am. Soc. Prev. Oncol. 16, 1229–1235 (2007).
28.

Shin, W. H. et al. Microglia expressing interleukin-13 undergo cell death and contribute

to neuronal survival in vivo. Glia 46, 142–152 (2004).
29.

Terabe, M., Park, J. M. & Berzofsky, J. A. Role of IL-13 in regulation of anti-tumor

immunity and tumor growth. Cancer Immunol. Immunother. CII 53, 79–85 (2004).
30.

Song, B. et al. A case-control study: association of SMAD7 single nucleotide

polymorphisms with colorectal cancer in the Han population. 9.
31.

Thompson, C. L. et al. Association of common genetic variants in SMAD7 and risk of

colon cancer. Carcinogenesis 30, 982–986 (2009).

25

32.

Slattery, M. L. et al. Increased Risk of Colon Cancer Associated with a Genetic

Polymorphism of SMAD7. Cancer Res. 70, 1479–1485 (2010).
33.

Boulay, J.-L. et al. SMAD7 is a prognostic marker in patients with colorectal cancer. Int.

J. Cancer 104, 446–449 (2003).
34.

Bankaitis, K. V. & Fingleton, B. Targeting IL4/IL4R for the treatment of epithelial

cancer metastasis. Clin. Exp. Metastasis 32, 847–856 (2015).
35.

Schwartzbaum, J. et al. Polymorphisms associated with asthma are inversely related to

glioblastoma multiforme. Cancer Res. 65, 6459–6465 (2005).

26

